This inventor holds 14 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Kyorin Pharmaceutical Co., Ltd., Teijin Pharma Limited. Active years: 1999-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 1999-2016
Title: The Innovations of Yoshikazu Asahina
Introduction
Yoshikazu Asahina is a prominent inventor based in Tochigi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with hypoglycemic effects. With a total of 14 patents to his name, Asahina's work has the potential to impact the treatment and prevention of diabetes and obesity.
Latest Patents
One of Asahina's latest patents involves a cyclopentylacrylamide derivative. This compound is designed to have a hypoglycemic effect and is useful for treating or preventing diabetes and obesity. The compound is represented by a specific general formula, where the components can vary, including hydrogen atoms, halogen atoms, and various functional groups. This innovative approach highlights Asahina's commitment to addressing critical health issues through his inventions.
Career Highlights
Throughout his career, Yoshikazu Asahina has worked with notable companies such as Kyorin Pharmaceutical Co., Ltd. and Teijin Pharma Limited. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in pharmaceutical research and development.
Collaborations
Asahina has collaborated with esteemed colleagues, including Yasumichi Fukuda and Koji Murakami. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Yoshikazu Asahina's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to pave the way for advancements in the treatment of diabetes and obesity.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile